GSK256073
GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2) . GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM) and dyslipidemia[1][2]. GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
Product Specifications
CAS Number
862892-90-8
Product Name Alternative
BafA1
UNSPSC
12352005
Hazard Statement
H302, H361
Target
GPR109A
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/gsk256073.html
Concentration
10mM
Purity
99.39
Solubility
DMSO : 16.67 mg/mL (ultrasonic)
Smiles
O=C(N(C1=C2NC(Cl)=N1)CCCCC)NC2=O
Molecular Formula
C10H13ClN4O2
Molecular Weight
256.69
Precautions
H302, H361
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD45RO (UCHL-1), CF640R conjugate, 0.1mg/mL
IgA Secretory Component (SC05), CF488A conjugate, 0.1mg/mL
Cytokeratin 18 (KRT18/834), CF640R conjugate, 0.1mg/mL
CD45RB (PTPRC/1147), CF488A conjugate, 0.1mg/mL
